Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | CGS Administrators | Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Repeat Germline Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Predictive Classifiers for Early Stage Non-small Cell Lung Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | Immune Thrombocytopenia (ITP) Therapy | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Blood Product Molecular Antigen Typing | Criteria changed |
| May 17, 2026 | CGS Administrators | Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Pigmented Lesion Assay | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Next-Generation Sequencing for Solid Tumors | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Plasma-Based Genomic Profiling in Solid Tumors | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Melanoma Risk Stratification Molecular Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Envisiaâ¢, Veracyteâ¢, Idiopathic Pulmonary Fibrosis Diagnostic Test | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Inivataâ¢, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Breast Cancer Index® (BCI) Gene Expression Test | Criteria changed |
| May 17, 2026 | CGS Administrators | Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the treatment of neurologic conditions | Criteria changed |
| May 17, 2026 | CGS Administrators | MDS FISH | Criteria changed |
| May 17, 2026 | CGS Administrators | Cystatin C Measurement | Criteria changed |
| May 17, 2026 | CGS Administrators | Micro-Invasive Glaucoma Surgery (MIGS) | Criteria changed |
| May 17, 2026 | CGS Administrators | Frequency of Hemodialysis | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: EndoPredict Breast Cancer Gene Expression Test | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Prometheus IBD sgi Diagnostic® Policy | Criteria changed |
| May 17, 2026 | CGS Administrators | Chiropractic Services | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: DecisionDx-UM (Uveal Melanoma) | Criteria changed |
| May 17, 2026 | CGS Administrators | Coenzyme Q10 (CoQ10) | Criteria changed |
| May 17, 2026 | CGS Administrators | Bladder/Urothelial Tumor Markers | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Healthâ¢) | Criteria changed |
| May 17, 2026 | CGS Administrators | GlycoMark® Testing for Glycemic Control | Criteria changed |
| May 17, 2026 | CGS Administrators | Polysomnography and Other Sleep Studies | Criteria changed |
| May 17, 2026 | CGS Administrators | Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities | Criteria changed |
| May 17, 2026 | CGS Administrators | ProMark® Risk Score | Criteria changed |
| May 17, 2026 | CGS Administrators | Proton Beam Therapy | Criteria changed |
| May 17, 2026 | CGS Administrators | <b> MolDX: HLA-DQB1*06:02 Testing for Narcolepsy</b> | Criteria changed |
| May 17, 2026 | CGS Administrators | Transcranial Magnetic Stimulation (TMS) | Criteria changed |
| May 17, 2026 | CGS Administrators | Bone Mass Measurement | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Breast Cancer Assay: Prosigna® | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Biomarkers in Cardiovascular Risk Assessment | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: MGMT Promoter Methylation Analysis | Criteria changed |
| May 17, 2026 | CGS Administrators | Urine Drug Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Molecular Diagnostic Tests (MDT) | Criteria changed |
| May 17, 2026 | CGS Administrators | Special Histochemical Stains and Immunohistochemical Stains | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR) | Criteria changed |
| May 17, 2026 | CGS Administrators | Somatosensory Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | Nerve Conduction Studies and Electromyography | Criteria changed |
| May 17, 2026 | CGS Administrators | Intravenous Immune Globulin | Criteria changed |
| May 17, 2026 | CGS Administrators | MolDX: NRAS Genetic Testing | Criteria changed |
| May 17, 2026 | CGS Administrators | Nerve Blocks for Peripheral Neuropathy | Criteria changed |
| May 17, 2026 | CGS Administrators | Transtelephonic Spirometry | Criteria changed |
| May 17, 2026 | CGS Administrators | Stretta Procedure | Criteria changed |
| May 17, 2026 | CGS Administrators | Psychological Services Coverage under the Incident to Provision for Physicians and Non-physicians | Criteria changed |